About Metsera, Inc.
https://metsera.comMetsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity.
CEO
Christopher Whitten Bernard
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 2
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
FMR LLC
Shares:13.89M
Value:$979.39M
VANGUARD GROUP INC
Shares:5.82M
Value:$410.66M
JANUS HENDERSON GROUP PLC
Shares:5.35M
Value:$377.37M
Summary
Showing Top 3 of 154
About Metsera, Inc.
https://metsera.comMetsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $122.08M ▲ | $-116.23M ▼ | 0% | $-1.11 ▼ | $-116.21M ▼ |
| Q2-2025 | $0 | $71.12M ▼ | $-68.72M ▲ | 0% | $-0.66 ▲ | $-68.67M ▲ |
| Q1-2025 | $0 | $79.81M ▲ | $-76.59M ▼ | 0% | $-0.74 ▼ | $-76.48M ▲ |
| Q4-2024 | $0 | $64.5M ▼ | $-52.87M ▲ | 0% | $-0.51 ▲ | $-132.58M ▼ |
| Q3-2024 | $0 | $111.27M | $-109.65M | 0% | $-2.2 | $-109.95M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $448.46M ▼ | $567.64M ▼ | $230.45M ▲ | $337.19M ▼ |
| Q2-2025 | $530.92M ▼ | $639.66M ▼ | $190.43M ▲ | $449.23M ▼ |
| Q1-2025 | $588.34M ▲ | $690.7M ▲ | $185.31M ▲ | $505.39M ▲ |
| Q4-2024 | $352.45M ▲ | $450.99M ▲ | $163.64M ▲ | $287.35M ▲ |
| Q3-2024 | $187.59M | $287.27M | $157.48M | $129.79M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-116.23M ▼ | $-81.72M ▼ | $0 ▲ | $422K ▲ | $-82.46M ▼ | $-81.72M ▼ |
| Q2-2025 | $-68.72M ▲ | $-58.96M ▼ | $-191K ▼ | $-1.51M ▼ | $-57.42M ▼ | $-59.16M ▼ |
| Q1-2025 | $-76.59M ▼ | $-54.34M ▼ | $-7K ▼ | $288.56M ▲ | $235.89M ▲ | $-54.35M ▼ |
| Q4-2024 | $-52.87M ▲ | $-36.37M ▼ | $-1K ▼ | $202.16M ▲ | $164.85M ▲ | $-36.38M ▼ |
| Q3-2024 | $-109.65M | $-28.3M | $0 | $139.43M | $111.23M | $-28.3M |
CEO
Christopher Whitten Bernard
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 2
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
FMR LLC
Shares:13.89M
Value:$979.39M
VANGUARD GROUP INC
Shares:5.82M
Value:$410.66M
JANUS HENDERSON GROUP PLC
Shares:5.35M
Value:$377.37M
Summary
Showing Top 3 of 154